ANTIDEPRESSANTS IN ANXIETY DISORDERS--DISCONTINUATION/MAINTENANCE W/ IMIPRAMINE

这项研究的主要目标是评估)/丙咪嗪停药后复发恶化的程度和测试假设维修等的药物保护逆转总实验样本100例惊恐障碍和广场恐怖症显示良好和稳定的响应系统开放6个月治疗随机化前12个月的前瞻性对照中止/维护阶段的研究;b)通过将双盲安慰剂替代条件的观察期延长至24个月来评估晚期复发/逆转；c)对停止1年维持治疗后12个月内的复发进行对照评估d)对研究完成者和复发者以及从双盲方案的各个阶段退出的受试者进行3至4年的随访，以收集系统的纵向和临床相关数据，特别是与不同长度的丙咪嗪维持治疗后复发相关的数据。采用的方法包括6个月的初始开放治疗阶段。对治疗反应良好的患者被随机分配到双盲治疗组，安慰剂组或继续用药12个月。然后发生第二次随机化；安慰剂组继续服用安慰剂，而服药组再次随机选择服用安慰剂或继续服药。我们招募了44名受试者，其中6名已进入第二随机化阶段。

The main objectives of the study are a) to assess the extent of worsening/relapse upon discontinuation of imipramine and to test the hypothesis that maintenance on the drug protects from such reversal in a total experimental sample of 100 subjects with panic disorder and agoraphobia who have shown good and stable response to 6 months of systematic open treatment prior to randomization to the 12 month prospective placebo controlled discontinuation/maintenance phase of the study; b) An evaluation of late relapse/reversals achieved by extending the observation period of the double-blind placebo substitution condition to 24 months; c) A controlled assessment of relapse within the 12 month period following discontinuation of 1 year maintenance treatment d) A follow-up for 3 to 4 years from initial randomization of study completers and relapsers who are retreated as well as subjects who drop out from various stages of the double-blind protocol in order to gather systematic longitudinal and clinically relevant data specifically as they relate to relapse after varying lengths of imipramine maintenance treatment. The methods employed include an initial open treatment phase for 6 months. Patients who show a good response to treatment are randomized to double-blind treatment to either placebo or continuation of medication for 12 months. A second randomization then occurs; the placebo group continues on placebo and the medication group is randomized again to either placebo or continuation of the medication. We have enrolled 44 subjects and six have reached the 2nd randomization stage.